AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer.
May 28, 2026 07:20 AM EDT
Pharma
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
Ayisha Sharma
News Reporter
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent…
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a…
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step…
